Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma.[ Read More ]
The intrinsic value of one BMY stock under the base case scenario is HIDDEN Compared to the current market price of 56.2 USD, Bristol-Myers Squibb Company is HIDDEN
Current Assets | 31.8 B |
Cash & Short-Term Investments | 12.3 B |
Receivables | 15.3 B |
Other Current Assets | 4.23 B |
Non-Current Assets | 63.4 B |
Long-Term Investments | 2.5 B |
PP&E | 8.04 B |
Other Non-Current Assets | 52.9 B |
Current Liabilities | 22.3 B |
Accounts Payable | 3.26 B |
Short-Term Debt | 3.28 B |
Other Current Liabilities | 15.7 B |
Non-Current Liabilities | 43.4 B |
Long-Term Debt | 38.2 B |
Other Non-Current Liabilities | 5.23 B |
Revenue | 45 B |
Cost Of Revenue | 10.7 B |
Gross Profit | 34.3 B |
Operating Expenses | 34.3 B |
Operating Income | 16.6 B |
Other Expenses | 8.56 B |
Net Income | 8.04 B |
Net Income | 8.04 B |
Depreciation & Amortization | 9.76 B |
Capital Expenditures | -1.21 B |
Stock-Based Compensation | 518 M |
Change in Working Capital | -1.91 B |
Others | 378 M |
Free Cash Flow | 12.7 B |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
1 week ago
Nov 04, 2024
|
Sell 38.9 K USD
|
Holzer Phil M
SVP and Controller |
- 700
|
55.615 USD |
2 weeks ago
Nov 01, 2024
|
Bought 100 K USD
|
Hirawat Samit
EVP,Chief Med.Offr.,Drug Dev. |
+ 1830
|
54.675 USD |
11 months ago
Dec 05, 2023
|
Bought 99.6 K USD
|
BOERNER CHRISTOPHER S.
Chief Executive Officer |
+ 2000
|
49.78 USD |
11 months ago
Nov 28, 2023
|
Bought 150 K USD
|
BOERNER CHRISTOPHER S.
Chief Executive Officer |
+ 3071
|
48.86 USD |
11 months ago
Nov 20, 2023
|
Bought 423 K USD
|
Samuels Theodore R. II
Director |
+ 8500
|
49.81 USD |
1 year ago
Aug 24, 2023
|
Sell 1.1 M USD
|
Powell Ann
EVP, Chief Human Resources |
- 17986
|
61.25 USD |
1 year ago
Aug 03, 2023
|
Sell 44.8 K USD
|
Plenge Robert M
EVP, Chief Research Officer |
- 732
|
61.14 USD |
1 year ago
May 03, 2023
|
Sell 3.38 M USD
|
VESSEY RUPERT
EVP & President, Research |
- 50385
|
67.06 USD |
1 year ago
Feb 06, 2023
|
Sell 17.9 M USD
|
Caforio Giovanni
Board Chair and CEO |
- 240000
|
74.65 USD |
1 year ago
Feb 06, 2023
|
Sell 835 K USD
|
Powell Ann
EVP, Chief Human Resources |
- 11183
|
74.69 USD |
2 years ago
Nov 09, 2022
|
Sell 1.31 M USD
|
Powell Ann
EVP, Chief Human Resources |
- 16250
|
80.45 USD |
2 years ago
Nov 07, 2022
|
Sell 3.62 M USD
|
VESSEY RUPERT
EVP, Research & Early Dev. |
- 45910
|
78.88 USD |
2 years ago
Sep 20, 2022
|
Sell 1.74 M USD
|
Caforio Giovanni
Board Chair and CEO |
- 25000
|
69.71 USD |
2 years ago
Sep 15, 2022
|
Sell 3.59 M USD
|
Caforio Giovanni
Board Chair and CEO |
- 50000
|
71.84 USD |
2 years ago
Sep 13, 2022
|
Sell 7.41 M USD
|
Elkins David V
EVP, Chief Financial Officer |
- 103951
|
71.29 USD |
2 years ago
Sep 13, 2022
|
Sell 2.14 M USD
|
Elkins David V
EVP, Chief Financial Officer |
- 30000
|
71.35 USD |
2 years ago
Sep 14, 2022
|
Sell 1.77 M USD
|
Powell Ann
EVP, Chief Human Resources |
- 25000
|
70.75 USD |
2 years ago
Jun 13, 2022
|
Sell 2.22 M USD
|
Caforio Giovanni
Board Chair and CEO |
- 30000
|
74.04 USD |
2 years ago
Jun 06, 2022
|
Sell 4.87 M USD
|
LEUNG SANDRA
EVP, General Counsel |
- 65000
|
74.89 USD |